Patent filing update, N4 Pharma PLC, 2020-05-18

RNS Number : 2398N
N4 Pharma PLC
18 May 2020

18 May 2020

N4 Pharma Plc

(“N4 Pharma” or the “Company“)


Patent filing update


N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, provides an update on its patent application for Nuvec®, filed in November 2018 (no. PCT/GB2018/053298).


As announced on 15 November 2018, the Company filed a Patent Cooperation Treaty (“PCT”) patent application for improvements made to the manufacturing process for its Nuvec® system. Under the terms of the PCT application process and following conclusion of the national phasing, the Company is now required to make specific applications in the territories in which it wishes to gain patent protection.


In consideration of this, the Company is filing ongoing patent applications in the following territories: Europe (including the UK); USA; Japan; India; Australia; Canada; and China. These additional applications, if successful, claim priority from the Company’s United Kingdom patent application number 1718817.8. 


Nigel Theobald, Chief Executive Officer of the Company, commented:


“We are seeking additional protection in the territories listed above, which the Board believes would provide maximum patent coverage for our PCT application whilst minimising outgoing expenditure. If the patents are granted in these regions, the Company will maintain its strong commercial protection of Nuvec®.”




N4 Pharma Plc

Nigel Theobald, CEO


Via Scott PR


Allenby Capital Limited

James Reeve/Asha Chotai


Tel: +44(0)203 328 5656

Turner Pope Investments (TPI) Ltd

Andrew Thacker


Tel: +44(0)20 3657 0050

Scott PR

Georgia Smith



Tel: +44(0)1477 539 539



About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec®.


N4 Pharma’s business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit




Leave a Reply

Your email address will not be published.